Nucleome Therapeutics Raises £37.5M in Series A Financing
- Nucleome Therapeutics, an Oxford, UK-based biotechnology company decoding the dark matter of the human genome, raised £37.5M in Series A funding
- The round was led by M Ventures, with participation from JJDC, Pfizer Ventures, British PatientCapital, through its Future Fund: Breakthrough programme, and Oxford Science Enterprises
- The company intends to use the funds to advance its autoimmune disease programs, accelerate expansion of its dark genome atlas and further develop its platform
- NucleomeTherapeutics is decoding the dark matter of the human genome to uncover novel ways to treat disease
- The dark genome holds more than 90% of disease-linked genetic variants whose value remains untapped, representing a significant opportunity for drug discovery and development
- The company has the ability to link these variants to gene function and precisely map disease pathways
